Posted on 28 August 2020
The UK Coronavirus Immunology Consortium (UK-CIC) combines the expertise of scientists from 17 institutions including the University of York and will work to identify how the immune system responds to SARS-CoV-2 – the virus which causes COVID-19.
The research is critical to understanding the many unknowns around the novel virus – for example, why it makes some people sick and not others, what constitutes effective immunity and how long might that immunity last.
To address the need for rapid and effective progress in our knowledge of COVID-19 and the immune system, the UK Coronavirus Immunology Consortium has received £6.5million of funding over 12 months from UK Research and Innovation (UKRI) and the National Institute for Health Research (NIHR). This represents the largest immunology grant awarded to tackle the COVID-19 pandemic.
UK-CIC aims to deliver meaningful benefits for public health by providing insights critical for improving patient care, developing new therapies, assessing immunity within the population and developing diagnostics and vaccines.
UK-CIC sets out to answer five key questions that will help the global coronavirus response:
Paul Kaye, Professor of Immunology at Hull York Medical School at the University of York, said: “Our research team at York, together with colleagues in Cambridge, Cardiff and Newcastle, will be taking the lead on addressing the question of how our immune system contributes to the damage caused to different body organs after SARS-CoV-2 infection and whether treatments that modulate specific immune responses might therefore be beneficial. We will also be looking at the role the immune system plays in determining variation in susceptibility to primary infection with COVID-19 and how this varies across the life course.
“The coronavirus pandemic poses a global challenge of enormous magnitude and this nationally-coordinated effort will enable us to work together, harnessing technologies and expertise not available within a single institute, to bring about meaningful benefits for patients.”
The Consortium will collaborate closely with ISARIC-4C, an internationally-leading project already underway to examine the immune profile of hospitalised patients with COVID-19, and is supported by the British Society for Immunology.
Professor Paul Moss, UK-CIC Principal Investigator of the Consortium from the University of Birmingham, said: “Understanding the complexities of the immune response to SARS-CoV-2 is key to successfully developing new diagnostics, treatments and vaccines against COVID-19. UK-CIC will see the UK immunology community come together in an unprecedented way to answer questions that are crucial in helping us control this pandemic, such as how effective immunity is developed and why individuals respond differently to the disease.
“Immunologists are at the forefront of efforts to tackle the coronavirus pandemic and the UK is a world-leader in immunology research. It’s an honour to lead this consortium to deliver a co-ordinated and agile national research programme to build our knowledge of this disease, which will translate into meaningful benefit for patients. There is so much that we still need to learn about how the novel coronavirus interacts with our immune system and, with this investment, we have a unique opportunity to answer these key questions and hasten effective pandemic control.”
UK-CIC is jointly funded by UKRI and NIHR as part of their rolling call for research proposals on COVID-19. It is supported by the British Society for Immunology. The aims of UK-CIC were developed from the research priorities on immunology and COVID-19 set out in May 2020 by the Academy of Medical Sciences and British Society for Immunology expert taskforce on immunology and COVID-19.
Explore more of our research.